Video

Dr. Costales on Study of Adjuvant Therapy in Uterine Leiomyosarcoma

Anthony Costales, MD, gynecologic oncology fellow, Cleveland Clinic, discusses a study of adjuvant therapy for patients with uterine leiomyosarcoma.

Anthony Costales, MD, gynecologic oncology fellow, Cleveland Clinic, discusses a study of adjuvant therapy for patients with uterine leiomyosarcoma.

This study aimed to characterize the efficacy of adjuvant therapy versus observation in women with early-stage uterine confine leiomyosarcoma following complete resection. This is a rare tumor type, Costales says, so they used the National Cancer Database to gather 1000 patients for evaluation.

Investigators were able to evaluate patients from 3 tumor types—leiomyosarcoma, epithelioid leiomyosarcoma, and myxoid leiomyosarcoma. Patients were then stratified based on adjuvant therapy such as chemotherapy, radiation, chemoradiation, or observation. Statistical software provided by the National Cancer Database was then utilized to analyze particular factors associated with trends of either adjuvant treatment or observation, explains Costales.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP